Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis

Allergy and Asthma Proceedings

Volumn 33, Issue 3, 2012, Pages 265-274

  Meier, Edward J ^a   Torkildsen, Gail L ^b   Gow, James A ^c   McNamara, Timothy R ^c   Gomes, Paul J ^d   Williams, Jon I ^c  

^a Eye Care Associates of Greater Cincinnati Inc   (United States)

^b Andover Eye Associates   (United States)

^c ISTA Pharmaceuticals Inc   (United States)

^d Ora Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EYE DROPS; PLACEBO;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; PHASE 3 CLINICAL TRIAL; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; SCREENING; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIPRURITICS; CHILD; CONJUNCTIVITIS, ALLERGIC; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PIPERIDINES; PRURITUS; PYRIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862564039     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2012.33.3570     Document Type: Article

References (44)

1. Marple BF, Fornadley JA, Patel AA, et al. Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 136:S107-S124, 2007.
2. Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 62(suppl 85):9-16, 2007.
3. Bernstein JA. Allergic and mixed rhinitis: Epidemiology and natural history. Allergy Asthma Proc 31:365-369, 2010.
4. Bielory L. Allergic and immunologic disorders of the eye. Part II: Ocular allergy. J Allergy Clin Immunol 106:1019-1032, 2000.
5. Settipane RA. Demographics and epidemiology of allergic and nonallergic rhinitis. Allergy Asthma Proc 22:185-189, 2001.
6. Chigbu DI. The management of allergic eye diseases in primary eye care. Cont Lens Anterior Eye 32:260-272, 2009.
7. Bielory L. Allergic conjunctivitis and the impact of allergic rhinitis. Curr Allergy Asthma Rep 10:122-134, 2010.
8. Singh K, Axelrod S, and Bielory L. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 126:778-783, 2010.
9. Raizman MB. Results of a survey of patients with ocular allergy treated with topical ketorolac tromethamine. Clin Ther 17:882-890, 1995.
10. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 344:30-37, 2001.
11. Abelson MB, Smith L, and Chapin M. Ocular allergic disease: Mechanisms, disease sub-types, treatment. Ocul Surf 1:127-149, 2003.
12. Broide DH. Allergic rhinitis: Pathophysiology. Allergy Asthma Proc 31:370-374, 2010.
13. Chapel H, Haeney M, Mishba S, et al. (Eds). Chapter 4: Anaphylaxis and allergy. In Essentials of Clinical Immunology, ed. 5. Malden, MA: Blackwell Publishing, 78-94, 2007.
14. Abbas AK, Lichtman AH, and Pillai S (Eds). Chapter 19: Immediate hypersensitivity. In Cellular and Molecular Immunology, ed. 6. Philadelphia, PA: Saunders Elsevier, 441-461, 2010.
15. Petrov A, and Fireman P. Chapter 1: Immunology of allergic and clinical immunologic disorders. In Atlas of Allergies and Clinical Immunology, ed. 3. Fireman P (Ed). Philadelphia, PA: Mosby Elsevier, 1-33, 2006.
16. Ohbayashi M, Manzouri B, Morohoshi K, et al. Chapter 5: The role of histamine in ocular allergy. In Histamine in Inflammation. Thurmond RL (Ed). New York, NY: Landes Bioscience and Springer Science+Business Media, 43-52, 2010.
17. Bacon AS, Ahluwalia P, Irani AM, et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol 106:948-954, 2000.
18. Abelson MB, and Welch DL. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand Suppl 78:60-63, 2000.
19. Bielory L, and Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 28:43-58, 2008.
20. Ueno M, Inagaki N, Nagai H, et al. Antiallergic action of betotastine besilate (TAU-284) in animal models: a comparison with ketotifen. Pharmacology 57:206-214, 1998.
21. Murata T, Matsumoto Y, Suzuki T, et al. Effects of the new allergy drug betotastine besilate (TAU-284) on experimental allergic rhinitis [in Japanese]. Allergy 46:576-584, 1997.
22. Baba S, Takasaki T, Baba K, et al. Late phase II clinical study of TAU-284 for perennial allergic rhinitis - Dose finding study by the double-blind method [in Japanese]. J Clin Ther Med 13:1259-1286, 1997.
23. Baba S, Takasaka T, Baba K, et al. Long-term treatment of TAU-284 (betotastine besilate) on perennial allergic rhinitis [in Japanese]. J Clin Ther Med 13:1361-1382, 1997.
24. Ishibashi Y, Harada S, Niimura M, et al. Late phase II study of TAU-284 (betotastine besialte) on chronic urticaria - Optimal dose finding study by double-blind technique [in Japanese]. J Clin Ther Med 13:1237-1257, 1997.
25. Abelson MB, Torkildsen GL, Williams JI, et al. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 31:1908-1921, 2009.
26. Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol 150:122-127, 2010.
27. Wingard JB, and Mah FS. Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis. Clin Ophthalmol 5:201-207, 2011.
28. Williams JI, Gow JA, Klier SM, et al. Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate. Curr Med Res Opin 26:2329-2338, 2010.
29. Kida T, Atsuko F, Sakai O, et al. Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models. Exp Eye Res 91:85-91, 2010.
30. Kato M, Nishida A, Aga Y, et al. Pharmacokinetic and pharmacodynamics evaluation of central effect of the novel antiallergic agent betotastine besilate. Drug Res 47:1116-1124, 1997.
31. Yato N, Murata T, Saito N, et al. Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug. Folia Pharmacol Jpn 110:19-29, 1997.
32. Baba S, Sakakura Y, Iwata S, et al. Early phase II study of TAU-284 (betotastine besilate) on perennial allergic rhinitis [in Japanese]. J Clin Ther Med 13:1217-1235, 1997.
33. Tanabe Seiyaku Co., Ltd. Talion package insert. Osaka, Japan; October 2009.
34. Kawana S, Niimi Y, Higashi N, et al. Efficacy and safety investigation of bepotastine besilate (Talion tablets) in patients with atopic dermatitis [in Japanese]. J New Rem Clin 54:1325-1331, 2005.
35. Koda F, and Furue M. Immediate clinical effectiveness of bepotastine besilate on urticaria [in Japanese]. Nishinihon J Dermatol 68:544-547, 2006.
36. Ishibashi Y, Harada S, Niimura M, et al. Early phase II study of TAU-284 (Betotastine besilate) on chronic urticaria [in Japanese]. J Clin Ther Med 13:1199-1215, 1997.
37. Ishibashi Y, Harada S, Niimura M, et al. Long-term treatment of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese]. J Clin Ther Med 13:1337-1359, 1997.
38. Ishibashi Y, Harada S, Niimura, et al. Clinical evaluation of TAU-284 (Betotastine Besilate) on eczema/dermatitis, prurigo and pruritus cutaneus [in Japanese]. J Clin Ther Med 13:1383-1400, 1997.
39. Abelson MB, Chambers WA, and Smith LM. Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 108:84-88, 1990.
40. Abelson MB, and Loeffler O. Conjunctival allergen challenge: Models in the investigation of ocular allergy. Curr Allergy Asthma Rep 3:363-368, 2003.
41. Abelson M, Howes J, and George M. The conjunctival provocation test model of ocular allergy: Utility for assessment of an ocular corticosteroid, loteprednol etabonate. J Ocul Pharmacol Ther 14:533-542, 1998.
42. Abelson MB, and Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 125:797-804, 1998.
43. Williams JI, Kennedy KS, Gow JA, et al. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. J Ocul Pharmacol Ther 27:385-393, 2011.
44. BEPREVE [package insert]. Irvine, CA: ISTA Pharmaceuticals, Inc; www.bepreve.com/assets/pdfs/Bepreve-Full-PI.pdf; 2010.